As many as 43,360 shares changed hands in the counter on BSE.

The stock depreciated at the beginning of June 2006. From a close of Rs 320.65 on 1 June, the scrip ended at Rs 252.10 on 14 June. Here, it found support and began appreciating to settle at Rs 313.80 on 6 July 2006.

Alembic has informed that a meeting of the Board of Directors will be held on 18 July 2006, to consider unaudited financial results for the first quarter ended on 30 June 2006 (April, 2006 to June, 2006) and sub-division of equity shares.

Earlier in March, Alembic’s management had decided to merge its subsidiary Alembic Glass with Shreno, an unlisted promoter-controlled entity.

One of the oldest pharmaceutical companies in India, Alembic, formerly known as Alembic Chemical Works Company, was founded in 1907. It manufactures pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations.

The company has set up a formulation manufacturing facility at Baddi in Himachal Pradesh with a capital investment of Rs 28 crore spread over 19,000 sq.mts and the plant has 900 million tablets and 600 million liquid oral bottles production capacity annually. Further the company has invested Rs.21.6 crore for a new 1,20,000 sq.ft R&D facility.

Alembic has reported a 33.3% growth in its topline for Q4 ended March 2006 to Rs 143.96 crore from Rs 107.98 crore a year earlier. The bottomline grew a whopping 168.9% for the same period to Rs 17.10 crore (Rs 6.36 crore).

For the full-year ended March 2006, Alembic has posted a 21.3% increase in net sales to Rs 630.88 crore (Rs 520.07crore). The bottomline for the same year spurted 50.9%, to Rs 78.52 crore (Rs 52.05 crore).